Former FDA commissioner Califf to pharma: opening up on health data requires overcoming risk

Former FDA commissioner Califf to pharma: opening up on health data requires overcoming risk

Califf spoke about the importance of more data to faster and cheaper drug development at the NewYorkBIO conference.

Drug list prices in DTC ads? Easier said than done

Drug list prices in DTC ads? Easier said than done

For one of President Trump's proposals for lowering the cost of drugs, the path to implementation could be long.

Read the May 2018 Digital Edition

Read the May 2018 Digital Edition

Read the May 2018 issue in its entirety.

The future of the agency model in a post-Sorrell era

The future of the agency model in a post-Sorrell era

As WPP faces break-up calls in the wake of Sir Martin Sorrell's exit, the agency holding company model is under greater scrutiny than at any time since the 1980s.

Five things for pharma marketers to know: Wednesday, May 16, 2018

Five things for pharma marketers to know: Wednesday, May 16, 2018

Novartis' top lawyer exits after Cohen payments; More states file suit against Purdue Pharma; J&J to relaunch baby line.

Whither the pharma Grand Prix? Questions abound in run-up to Cannes health fest

Whither the pharma Grand Prix? Questions abound in run-up to Cannes health fest

Whether jurors will award a pharma Grand Prix, and whether US pharma will show up, are two open questions in the run-up to Lions Health.

AstraZeneca's Joe Shields to launch Health Accelerators with Think Patients

AstraZeneca's Joe Shields to launch Health Accelerators with Think Patients

Shields will serve as president of the Think Patients subsidiary firm.

Five things for pharma marketers to know: Tuesday, May 15, 2018

Five things for pharma marketers to know: Tuesday, May 15, 2018

Feds join whistleblower case against Insys; Kleiner Perkins Caufield partner Seidenberg departs; Lilly strikes second acquisition deal in a week.

17 days that rocked WPP

17 days that rocked WPP

To say that Sir Martin Sorrell's rapid departure from WPP was a seismic event is an understatement. So just what happened in the days leading up to the fall of its CEO?

5 takeaways from Trump's drug pricing speech

5 takeaways from Trump's drug pricing speech

Pharma stocks were up after the President went easy on drugmakers.

Five things for pharma marketers to know: Monday, May 14, 2018

Five things for pharma marketers to know: Monday, May 14, 2018

Beam Therapeutics raises $87 million in Series A funding; Trump drug-pricing plan largely spares big pharma; Novartis regrets Cohen consulting pact.

Five things for pharma marketers to know: Friday, May 11, 2018

Five things for pharma marketers to know: Friday, May 11, 2018

Trump on drug pricing; Alexa breaks into healthcare; Merck's experimental Ebola vaccine headed to Congo outbreak.

Five things for pharma marketers to know: Thursday, May 10

Five things for pharma marketers to know: Thursday, May 10

Novartis discloses $1.2 million Cohen payment; FDA calls for two stem cell companies to halt operations; Eli Lilly to buy Armo Biosciences for $1.6 billion

Edelman names Susan Isenberg global health chair

Edelman names Susan Isenberg global health chair

Isenberg replaces Kym White, who left the PR agency in March to join Vertex Pharmaceuticals.

Five things for pharma marketers to know: Wednesday, May 9, 2018

Five things for pharma marketers to know: Wednesday, May 9, 2018

Novartis payments to Trump lawyer made public; Cardinal Health apologizes for mass painkiller shipments; Valeant plans rebranding.

Cannabis gets the iPhone treatment

Cannabis gets the iPhone treatment

Thanks to legalization, a new breed of startups are changing the nature of cannabis advertising.

Sorrell: 'I'm going to start again'

Sorrell: 'I'm going to start again'

The former WPP CEO said on Tuesday at Techonomy NYC 18 that he's not planning to retire.

Five things for pharma marketers to know: Tuesday, May 8, 2018

Five things for pharma marketers to know: Tuesday, May 8, 2018

Takeda, Shire reach a deal; Walmart to restrict opioid prescriptions; Glaxo launches global media review.

GSK reviews $1.76 billion global media

GSK reviews $1.76 billion global media

Pharma giant GlaxoSmithKline has reportedly launched a review of its $1.76 billion global media agency arrangements, putting MediaCom and PHD on alert.

Trust in health sector takes a hit in major markets, Edelman research finds

Trust in health sector takes a hit in major markets, Edelman research finds

The healthcare sector has suffered a dip in public trust in major markets including France, India and the US, but Britons remain among the more trusting globally, according to the Edelman Health Trust Barometer.

Five things for pharma marketers to know: Monday, May 7, 2018

Five things for pharma marketers to know: Monday, May 7, 2018

Elliott makes offer for AthenaHealth; J&J releases data from esketamine late-stage trial; Roche wins fast Tecentriq review from FDA.

If Sorrell was so influential, why can't adland agree on his legacy?

If Sorrell was so influential, why can't adland agree on his legacy?

For all the talk about "legacy," industry experts are struggling to agree on how Martin Sorrell will be remembered in years to come.

Merck's Gerberding, Publicis Health's Colucci call for courage in tackling gender parity

Merck's Gerberding, Publicis Health's Colucci call for courage in tackling gender parity

Both leaders were honored at Healthcare Businesswomen's Association 2018 Woman of the Year event in New York.

Six weeks until the Cannes Lions: Here's what we know

Six weeks until the Cannes Lions: Here's what we know

Record year for brands, fewer celebrities, lower volume of entries expected and much more.

Five things for pharma marketers to know: Friday, May 4, 2018

Five things for pharma marketers to know: Friday, May 4, 2018

Daraprim retains high price tag despite Shkreli sentencing; Merck invests $125 million in Moderna; Cigna posts better-than-expected Q1 earnings.

4 agencies making a difference in their communities and around the world

4 agencies making a difference in their communities and around the world

Four agencies are making a difference by supporting nonprofits, educating and empowering youth, and promoting wellness and sustainability in communities around the world

Five things for pharma marketers to know: Thursday, May 3, 2018

Five things for pharma marketers to know: Thursday, May 3, 2018

FDA and HHS officials talk drug pricing fixes; Merck pushes for another Keytruda approval; CVS reports better-than-expected Q1 earnings.

Infographic | A closer look at co-pay coupons and programs

Infographic | A closer look at co-pay coupons and programs

Intriguing data on the economics and impact of co-pay coupons and programs

Rbb Communications' Srikant Ramaswami on yoga, 'think time,' and his mentors

Rbb Communications' Srikant Ramaswami on yoga, 'think time,' and his mentors

Rbb Communications' EVP of global and emerging markets, healthcare Srikant Ramaswami discusses how he keeps sane with his busy schedule and what inspires him.

Five things for pharma marketers to know: Wednesday, May 2, 2018

Five things for pharma marketers to know: Wednesday, May 2, 2018

J&J's Janssen to buy BeneVir; Regulators approve new use of Kymriah; Deaths from synthetic opioids surpass prescription opioids.

A tale of two lung cancer immunotherapies: Merck's Keytruda takes the reins

A tale of two lung cancer immunotherapies: Merck's Keytruda takes the reins

Opdivo's commercial potential will likely take a hit in the wake of new Keytruda data, but the impact may depend on the ability of BMS to market the message that its I-O/I-O combo allows patients to delay chemo.

Innovative health gains highlight Pfizer's Q1

Innovative health gains highlight Pfizer's Q1

The unit was up 6% in the first quarter.

Five things for pharma marketers to know: Tuesday, May 1, 2018

Five things for pharma marketers to know: Tuesday, May 1, 2018

Fitbit partners with Google Cloud to make health data more shearable; Regeneron, Sanofi to slash price of Praluent for Express Scripts customers; Novo Nordisk teams up with startup to help diabetes patients.

Top 40 Healthcare Transformers of 2018

Top 40 Healthcare Transformers of 2018

Here are the 40 upstarts and veterans who are transforming the healthcare industry.

Cannabis organization proposes national advertising regulations

Cannabis organization proposes national advertising regulations

The National Association of Cannabis Businesses has released the first national advertising rules for the cannabis industry.

Mark Read interview: WPP must focus more on clients and less on how we organize ourselves

Mark Read interview: WPP must focus more on clients and less on how we organize ourselves

Mark Read has said WPP needs to focus more on clients and less on how it organizes itself.

Five things for pharma marketers to know: Monday, April 30, 2018

Five things for pharma marketers to know: Monday, April 30, 2018

Allergan migraine drug meets Phase III endpoints; WPP unit with health and wellness shops up 2% in Q1; Watchdog groups question CDC director's salary.

WPP begins post-Sorrell era with flat revenues as slowdown eases

WPP begins post-Sorrell era with flat revenues as slowdown eases

Revenue for WPP's health and wellness, brand consulting, and specialist communications unit grew 2% in first quarter of 2018 to $1.47 billion.

Sorrell's pay fell more than 70%, WPP annual report reveals

Sorrell's pay fell more than 70%, WPP annual report reveals

WPP's former chief executive Sir Martin Sorrell was paid a (relatively) measly £13.9m by the company in 2017, its annual report shows.

Five things for pharma marketers to know: Friday, April 27, 2018

Five things for pharma marketers to know: Friday, April 27, 2018

Trump looks for another VA nominee; CRISPR company Mammoth launches; Why autism cases are increasing.

Cannes Lions announces 2018 Pharma, Health and Wellness juries

Cannes Lions announces 2018 Pharma, Health and Wellness juries

The Lions Health part of the festival will take place on June 18 and 19

Havas 'co-operating with authorities' following Bolloré arrest

Havas 'co-operating with authorities' following Bolloré arrest

Havas has announced it is co-operating with authorities following the shock arrest of Vincent Bolloré.

Five things for pharma marketers to know: Thursday, April 26, 2018

Five things for pharma marketers to know: Thursday, April 26, 2018

FDA gives Acadia's Nuplazid another look; Americans for Prosperity launches campaign for "right to try"; Juno cofounder exits.

Colin McBean joins Astellas to oversee Americas branding

Colin McBean joins Astellas to oversee Americas branding

He is joining the pharma company from Archer Daniels Midland.

Harry Connick Jr. plays his part to stop colon cancer screening procrastination

Harry Connick Jr. plays his part to stop colon cancer screening procrastination

His wife, Jill Connick, also played a role in The New 50 campaign.

Five things for pharma marketers to know: Wednesday, April 25, 2018

Five things for pharma marketers to know: Wednesday, April 25, 2018

Takeda investors unhappy with preliminary Shire deal; New drug sales drive Amgen earnings; Novartis debuts mobile app for eye disease study.

Vincent Bolloré arrested as part of probe into corruption allegations

Vincent Bolloré arrested as part of probe into corruption allegations

The billionaire recently stepped down as chairman of Vivendi.

Consultancies are 'in the room, but not winning,' says WPP digital leader

Consultancies are 'in the room, but not winning,' says WPP digital leader

But threats to the industry loom as brands take work in-house.

How Adapt Pharma tackled the opioid crisis head on

How Adapt Pharma tackled the opioid crisis head on

The firm's Narcan product is more than just a lifesaving treatment for opioid overdose. It's a brilliant, salient campaign, as well.

How removing an 's' can change the perception of migraines

How removing an 's' can change the perception of migraines

Amgen and Novartis enlisted Arnold Worldwide, Wavemaker, and Starcom Media Group for its Speak Your Migraine campaign.

Five things for pharma marketers to know: Tuesday, April 24, 2018

Five things for pharma marketers to know: Tuesday, April 24, 2018

Express Scripts pressures Amgen on migraine medicine list price; Takeda, Shire get closer to deal; Sanofi R&D chief steps down.

Five things for pharma marketers to know: Monday, April 23, 2018

Five things for pharma marketers to know: Monday, April 23, 2018

Takeda makes higher offer for Shire; Prothena pulls plug on AL amyloidosis drug; Henry Schein to spin off animal health unit.

Sandoz signs on to lead launch of Pear's digital therapeutics

Sandoz signs on to lead launch of Pear's digital therapeutics

A deal with Sandoz to lead the global launch of Pear's two lead products puts marketing muscle behind the nascent class of 'prescription digital therapeutics.'

Lessons learned from going live on Facebook with a branded drug

Lessons learned from going live on Facebook with a branded drug

Novocure and Glue Advertising put on a Facebook Live event promoting the cancer treatment Optune in March.

Five things for pharma marketers to know: Friday, April 20, 2018

Five things for pharma marketers to know: Friday, April 20, 2018

Allergan reverses course on Shire deal; Merck seeks partners for cancer, immune system drugs; J&J diversified vision portfolio and it's paying off.

P&G: healthcare acquisition helps us stay on top of consumer 'megatrends'

P&G: healthcare acquisition helps us stay on top of consumer 'megatrends'

Procter & Gamble said its $4.2 billion acquisition of German firm Merck's consumer health division was about allowing it to respond to the changing demands of an aging world.

Private-equity funds dominate marcomms M&A

Private-equity funds dominate marcomms M&A

Nearly a quarter (22%) of all marcomms M&A deals involved private-equity funds — double the 11% seen in the last two quarters of 2017.

Five things for pharma marketers to know: Thursday, April 19, 2018

Five things for pharma marketers to know: Thursday, April 19, 2018

Allergan enters bidding war for Shire; Opioid prescriptions drop in 2017; Novartis Q1 numbers disappoint.

Read and Scott: 'We don't believe break-up of WPP makes sense'

Read and Scott: 'We don't believe break-up of WPP makes sense'

WPP's joint chief operating officers Mark Read and Andrew Scott have said they do not believe a break-up of the ad group makes sense.

Ogilvy CEO John Seifert on Martin Sorrell's exit: 'The show must go on'

Ogilvy CEO John Seifert on Martin Sorrell's exit: 'The show must go on'

Seifert said feedback from clients has been positive.

PBMs, drugmakers face off over copay accumulators

PBMs, drugmakers face off over copay accumulators

As with most drug pricing battles, patients yet again are caught in the crossfire.

Five things for pharma marketers to know: Wednesday, April 18, 2018

Five things for pharma marketers to know: Wednesday, April 18, 2018

Sanders introduces opioid bill; GW gets nod from FDA for Epidiolex; Sanofi sells generic unit to Advent for $2.4 billion.

The MM&M buyer's guide to boutique consulting services

The MM&M buyer's guide to boutique consulting services

You've seen what the biggies can do. What about the smaller end of the spectrum? MM&M's second buyer's guide to pharma, healthcare, and life sciences consulting services focuses on the dos and don'ts of hiring boutique firms.

Omnicom Health's CEO on agency consolidation and why Japan's healthcare market is a 'bellwether'

Omnicom Health's CEO on agency consolidation and why Japan's healthcare market is a 'bellwether'

The healthcare marketing group made another major acquisition in the country last month.

Omnicom beats estimates in Q1, but sees slight dip in North America

Omnicom beats estimates in Q1, but sees slight dip in North America

Omnicom's healthcare revenue was up 2.7% in Q1

Five things for pharma marketers to know: Tuesday, April 18, 2018

Five things for pharma marketers to know: Tuesday, April 18, 2018

J&J Q1 numbers beat expectations; Amazon scraps pharma product distribution plan; FDA works to develop regulatory processes for AI.

Sorrell on Sorrell: ex-WPP chief in his own words

Sorrell on Sorrell: ex-WPP chief in his own words

Campaign looks back at some of Sir Martin Sorrell's musings, barbs and pearls of wisdom in recent times.

Spectrum brings on biopharma, biotech, creative execs

Spectrum brings on biopharma, biotech, creative execs

The firm hired five senior staff in the past month.

Five things for pharma marketers to know: Monday, April 16, 2018

Five things for pharma marketers to know: Monday, April 16, 2018

Shire sale of oncology business makes it more affordable for Takeda; FDA reverses course on Alkermes depression drug; Sorrell out as WPP CEO.

Forensic, focused, cantankerous: nine reflections on Sorrell and his style

Forensic, focused, cantankerous: nine reflections on Sorrell and his style

As Sir Martin clears his desk, PRWeek has collected nine thoughts from the worlds of PR, journalism and agency life on the man, his skills, his temperament, and his future.

Sorrell exit could spell the end for WPP, analysts say

Sorrell exit could spell the end for WPP, analysts say

Martin Sorrell's resignation as chief executive of WPP could lead to a breakup of the company and spark other major changes.

Sorrell departs WPP: how an outsider shaped the global ad industry

Sorrell departs WPP: how an outsider shaped the global ad industry

John Tylee examines how a man who never ran an agency rose to become such a dominant force.

Sorrell quits as WPP chief executive

Sorrell quits as WPP chief executive

Martin Sorrell has stood down as chief executive of WPP, the company has announced.

WPP board to meet as Sorrell probe nears conclusion

WPP board to meet as Sorrell probe nears conclusion

WPP's board of directors is set to meet as it awaits the outcome of an investigation into the personal conduct of CEO Martin Sorrell.

Five things for pharma marketers to know: Friday, April 13, 2018

Five things for pharma marketers to know: Friday, April 13, 2018

FDA investigates unapproved herpes vaccine; DC launches PReP campaign; J&J ordered to pay $80 million in damages in asbestos suit.

Marian Salzman exits Havas PR for Philip Morris International

Marian Salzman exits Havas PR for Philip Morris International

She is relocating to Switzerland for the role.

Crisis communicators give Zuckerberg high marks for testimony

Crisis communicators give Zuckerberg high marks for testimony

The Facebook CEO did not wilt during this week's marathon Senate session.

Agency M&As up 126% globally, with U.S. leading the way

Agency M&As up 126% globally, with U.S. leading the way

U.S. deals through the end of March increased 366% compared with last year.

Pfizer signs 20-year lease for new New York City headquarters

Pfizer signs 20-year lease for new New York City headquarters

The pharma giant will take up 15 floors of a new Manhattan skyscraper.

Former GSW creative chief Dave Sonderman joins The Shipyard

Former GSW creative chief Dave Sonderman joins The Shipyard

Sonderman had worked at GSW since 2001.

Survey: Half of women don't focus on their own health

Survey: Half of women don't focus on their own health

GCI Health, HealthyWomen, and Redbook magazine are using survey insights to inform the HealthiHer movement.

Five things for pharma marketers to know: Wednesday, April 11, 2018

Five things for pharma marketers to know: Wednesday, April 11, 2018

Alexion buys Wilson in latest pharma deal; Drug performance software company Aetion gets financial backing; Roche stops enrollment in combo study after patient deaths.

Facebook share price rebounds after Zuckerberg's testimony

Facebook share price rebounds after Zuckerberg's testimony

Despite the US Congress's lack of insight into Facebook's operations, Mark Zuckerberg's handling of the situation seems to have restored investor confidence in the company.

Read the April 2018 Digital Edition

Read the April 2018 Digital Edition

Read the April 2018 issue in its entirety.

What's the state of diversity in healthcare agencies?

The 2018 MM&M/Publicis Health Diversity Survey is open.

Five things for pharma marketers to know: Tuesday, April 10, 2018

Five things for pharma marketers to know: Tuesday, April 10, 2018

White House to allow states to determine health benefits required by Obamacare; FDA orders Essure sales restrictions; Researchers recommend redefining Alzheimer's.

APCO hires Nancy Turett as healthcare executive director

APCO hires Nancy Turett as healthcare executive director

Turett spent 25 years at Edelman before launching her own firm in 2013.

Angela Gillespie named president of W2O WCG

Angela Gillespie named president of W2O WCG

Gillespie will report to W2O president Jennifer Gottlieb.

Arthur Sadoun: 'Nobody is talking about the client of the future'

Arthur Sadoun: 'Nobody is talking about the client of the future'

The industry is being disrupted and marketers are part of the equation.

Sorrell probe findings could land next week

Sorrell probe findings could land next week

WPP's investigation into alleged misconduct by founder and chief executive Sir Martin Sorrell could be concluded by next week, according to reports.

Five things for pharma marketers to know: Monday, April 9, 2018

Five things for pharma marketers to know: Monday, April 9, 2018

Novartis to buy AveXis; Merck lung cancer drug meets primary goal in trial; "Pharma bro" duo expose more drug pricing flaws.

When TV doctors call you to make an appointment

When TV doctors call you to make an appointment

Actor Patrick Dempsey is helping patients get over the pressure of scheduling an appointment

Five things for pharma marketers to know: Friday, April 6, 2018

Five things for pharma marketers to know: Friday, April 6, 2018

Facebook puts hospital patient data project on hold; Pharma companies' spending on advocacy under the microscope; Naloxone made more widely available.

Johnson & Johnson marketing executive Debra Bass joins Nuvo

Johnson & Johnson marketing executive Debra Bass joins Nuvo

She will lead Nuvo Group's U.S. operations and head marketing globally.

Five things for pharma marketers to know: Thursday, April 5, 2018

Five things for pharma marketers to know: Thursday, April 5, 2018

Gottlieb asks for internet providers' help fighting opioid crisis; Ferring acquires Rebiotix; AbbVie reaches deal with Biogen to delay Humira rival.

High-profile candidates challenge marketers well in advance of launch

High-profile candidates challenge marketers well in advance of launch

With pharma facing ongoing scrutiny of its pricing practices, medical marketers are increasingly asked to demonstrate the superior value of new therapies. High-profile candidates in immunology, pain management, and melanoma challenge marketers well in advance of launch.

Five things for pharma marketers to know: Wednesday, April 4, 2018

Five things for pharma marketers to know: Wednesday, April 4, 2018

Obamacare signup total misses 2017 numbers; Feds warn of "nightmare bacteria"; Lilly, startup reach $473 million deal on diabetes work.

Pro ad report 2017: Ad revenue plunged for print-first publishers

Pro ad report 2017: Ad revenue plunged for print-first publishers

The 2017 numbers aren't kind to print-first publishers. Is this a blip in print's fortunes or the start of a long-predicted decline?

Dr. Reddy's Laboratories CEO of developed markets Alok Sonig makes Wall Street listen

Dr. Reddy's Laboratories CEO of developed markets Alok Sonig makes Wall Street listen

Alok Sonig, chief executive officer of developed markets at Dr. Reddy's Laboratories, articulates the benefits of generics.

Read the March 2018 Digital Edition

Read the March 2018 Digital Edition

Read the March 2018 issue in its entirety.